SCHEMBL9924060

SCHEMBL9924060

COC(=O)CS(=O)(=O)Nc1nc2cc(C)ccn2c1C

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.45
ALDH1A1 P00352 4/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
HSD17B10 Q99714 1/20 0.45
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
THRB P10828 1/20 0.38
MAPT P10636 1/20 0.38
POLB P06746 2/20 0.37
TP53 P04637 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
GAA P10253 4/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
PKM P14618 1/20 0.36
GLA P06280 1/20 0.36
HPGD P15428 1/20 0.36
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9893272 0.85 KDM4E (0.38) KDM4EALDH1A1SMN1; SMN2HSD17B10MAPT
SCHEMBL9924057 0.70 KDM4E (0.74) KDM4EALDH1A1SMN1; SMN2HSD17B10NPC1
SCHEMBL9924052 0.69 KDM4E (0.45) KDM4EALDH1A1SMN1; SMN2HSD17B10NPC1
SCHEMBL6748602 0.68 KDM4E (0.49) KDM4EALDH1A1SMN1; SMN2HSD17B10NPC1
SCHEMBL5167958 0.67 ALDH1A1 (0.45) KDM4EALDH1A1SMN1; SMN2HSD17B10NPC1
SCHEMBL9924054 0.65 KDM4E (0.55) KDM4EALDH1A1SMN1; SMN2HSD17B10NPC1
SCHEMBL27225407 0.63 GAA (0.42) KDM4EALDH1A1SMN1; SMN2HSD17B10NPC1
SCHEMBL5166799 0.63 RAB9A (0.54) KDM4EALDH1A1SMN1; SMN2HSD17B10NPC1
SCHEMBL12832208 0.63 ALDH1A1 (0.59) KDM4EALDH1A1SMN1; SMN2HSD17B10MAPT
SCHEMBL15631150 0.63 KDM4E (0.71) KDM4EALDH1A1SMN1; SMN2HSD17B10NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9067935-B2 Imidazo[1,2-α]pyridine sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2015-06-30 US disclosed
US-20140088098-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2014-03-27 US disclosed
US-20120149699-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149699-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPV1, TRPM2 KDM4E 3480/4885ALDH1A1 2230/4885SMN1; SMN2 442/4885
US-20140088098-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPV1, TRPM2 KDM4E 3480/4885ALDH1A1 2230/4885SMN1; SMN2 442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.